ArticleFrontiers in oncology2025
CD20+ and CD204+ exhibit distinct prognostic associations in thymic epithelial tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thymic epithelial tumors (TETs), encompassing thymomas and thymic carcinomas, are rare malignancies originating from thymic epithelial cells. This study aimed to characterize tumor-infiltrating immune cells (TIIC) within the tumor microenvironment (TME) and evaluate their prognostic significance in TETs. Methods: We retrospectively analyzed 125 patients with surgically resected TETs (2009-2021). Immunohistochemical staining of tumor specimens was performed to assess TIIC distribution, with significant associations between immune markers and survival outcomes evaluated using Cox regression. Results: Among the analyzed markers, CD20, CD204, CD206, and CD47 emerged as potential predictors for disease-free survival (DFS), while CD20 and CD204 showed prognostic relevance for overall survival (OS). Specifically, stromal CD20+ TIIC density was independently associated with prolonged DFS(HR=4.74, 95% CI(1.673-13.434), P=0.003) and OS (HR=5.086, 95% CI(1.391-18.594), P=0.014), whereas elevated CD204+ TIIC infiltration correlated with reduced DFS(HR=0.154, 95% CI(0.043-0.547), P=0.004) and OS(HR=0.169, 95% CI(0.056-0.607), P=0.002). Conclusion: These findings suggest that targeting M2 macrophage-driven immunosuppression may enhance therapeutic efficacy in TETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.